

|   |                     |                |
|---|---------------------|----------------|
| <b>INFORMATION DISCLOSURE CITATION</b><br><br><b>PTO-1449</b> | Attorney Docket No. | Serial No.     |
|   | O/97277 US/D1       | To be assigned |
|   | Applicant           |                |
|   | STIEKEMA ET AL.     |                |
| Filing Date   | Group               |                |
| November 2, 2001  | To be assigned      |                |

## U.S. PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
|------------------|-----------------|------|------|-------|----------|----------------------------|
|                  | AA              |      |      |       |          |                            |
|                  | AB              |      |      |       |          |                            |
|                  | AC              |      |      |       |          |                            |
|                  | AD              |      |      |       |          |                            |
|                  | AE              |      |      |       |          |                            |
|                  | AF              |      |      |       |          |                            |
|                  | AG              |      |      |       |          |                            |
|                  | AH              |      |      |       |          |                            |
|                  | AI              |      |      |       |          |                            |

## FOREIGN PATENT DOCUMENTS

|              | Document Number | Date       | Country | Translation |
|--------------|-----------------|------------|---------|-------------|
| <i>87183</i> | AJ 0 084 999 A  | 08-03-1983 | EP      |             |
|              | AK              |            |         |             |
|              | AL              |            |         |             |
|              | AM              |            |         |             |
|              | AN              |            |         |             |
|              | AO              |            |         |             |
|              | AP              |            |         |             |
|              | AQ              |            |         |             |

## OTHER DOCUMENTS

*Long B*

|    |  |
|----|--|
| AR | BÉGUIN, S. ET AL.: "The Action of a Synthetic Pentasaccharide on Thrombin Generation in Whole Plasma", THROMBOSIS AND HEMOSTASIS, 61 (3) (1989), pages 397-401.  |
| AS | BARROWCLIFFE, T. ET AL.: "The Effect of $\text{Ca}^{2+}$ , phospholipid and Factor V on the anti-(Factor Xa) Activity of Heparin and Its High-Affinity Oligosaccharides", J. BIOCHEM, (1987) 243, pages 31-37.   |
| AT | EISENBERG, P. ET AL.: "Importance of Factor Xa in Determining the Procoagulant Activity of Whole-Blood Clots", J. CLIN. INVEST., Vol. 91, May 1993, pages 1877-1883.   |
| AU | MESSMORE ET AL.: "Clinical Efficacy of Heparin Fractions: Issues and Answers", CRIT. REV. IN CLIN. LAB. SCI., Vol. 23, Issue 2, 1986, pages 77-94.   |
| AV | LORMIEAU ET AL.: "The Effect of the Synthetic Pentasaccharide SR90107/ORG31540 on Thrombin Generation Ex Vivo is Uniquely Due to ATIII-Medicated Neutralization of Factor Xa", THROMBOSIS AND HAEMOSTASIS, Vol. 74, No. 6, December 1995, pages 1474-1477. |
| AW | VOGEL ET AL.: "Pentasaccharide and Orgaran® Arrest, whereas Heparin Delays Thrombus Formation in a Rat Arteriovenous Shunt", THROMBOSIS AND HAEMOSTASIS, Vol. 69, No. 1, 11 January 1993, pages 29-34.   |

**Examiner**

### Date Considered

Silvia Di Natale Baro

February 29, 2002

|   |                     |                |
|---|---------------------|----------------|
| INFORMATION DISCLOSURE CITATION<br><br>PTO-1449 | Attorney Docket No. | Serial No.     |
|   | O/97277 US/D1       | To be assigned |
|   | Applicant           |                |
|   | STIEKEMA ET AL.     |                |
| Filing Date                                     |                     | Group          |
| November 2, 2001                                |                     | To be assigned |

#### U.S. PATENT DOCUMENTS

| Examiner Initial |    | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
|------------------|----|-----------------|------|------|-------|----------|----------------------------|
|                  | AA |                 |      |      |       |          |                            |
|                  | AB |                 |      |      |       |          |                            |
|                  | AC |                 |      |      |       |          |                            |
|                  | AD |                 |      |      |       |          |                            |
|                  | AE |                 |      |      |       |          |                            |
|                  | AF |                 |      |      |       |          |                            |
|                  | AG |                 |      |      |       |          |                            |
|                  | AH |                 |      |      |       |          |                            |
|                  | AI |                 |      |      |       |          |                            |

#### FOREIGN PATENT DOCUMENTS

|  |    | Document Number | Date | Country | Translation |
|--|----|-----------------|------|---------|-------------|
|  | AJ |                 |      |         |             |
|  | AK |                 |      |         |             |
|  | AL |                 |      |         |             |
|  | AM |                 |      |         |             |
|  | AN |                 |      |         |             |
|  | AO |                 |      |         |             |
|  | AP |                 |      |         |             |
|  | AQ |                 |      |         |             |

#### OTHER DOCUMENTS

|                         |    |  |
|-------------------------|----|--|
| Soneb<br><br>J<br><br>✓ | AX | FREEDMAN, M.D.: "Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin", J. CLIN. PHARMACOL., Vol. 32, No. 7, 1992, pages 584-591.  |
|                         | AY | CADROY ET AL.: "Antithrombotic Effects of Synthetic Pentasaccharide with High Affinity for Plasma Antithrombin III in Non-Human Primates", THROMBOSIS AND HAEMOSTASIS, Vol. 70, No. 4, 18 October 1993, pages 631-635. |
|                         | AZ | BERNAT ET AL.: "The Synthetic Pentasaccharide SR 90107/Org 31540 Enhances Tissue-Type Plasminogen Activator-Induced Thrombolysis in Rabbits", FIBRINOLYSIS, Vol. 10, No. 3, 1996, pages 151-157.                       |
|                         | BA | SCHIELE ET AL.: "Initial Experience of Sulphated Pentasaccharide, A Pure Factor Xa Inhibitor, in Coronary Angioplasty", CIRCULATION, Vol. 94, No. 8suppl., 1996, page I742, Abstract No. 4340. ABSTRACT ONLY.          |

Examiner

Silvia O'Nole Bono

Date Considered

February 20, 2002